<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02502123</url>
  </required_header>
  <id_info>
    <org_study_id>GMA-CAN-NEU-0336</org_study_id>
    <nct_id>NCT02502123</nct_id>
  </id_info>
  <brief_title>Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®</brief_title>
  <acronym>PREDICT</acronym>
  <official_title>Multi-Centre, Prospective, Observational Study of Patient Reported Outcomes in Patients Diagnosed With Chronic Migraine and Treated With OnabotulinumtoxinA for Injection (BOTOX®) (PREDICT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will prospectively assess long term heath related quality of life in chronic
      migraine patients currently being treated with OnabotulinumtoxinA for injection (BOTOX®) as
      standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2, 2015</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Migraine-Specific Quality of Life (MSQ) at Treatment 4 Using a 6-Item Questionnaire</measure>
    <time_frame>Baseline, Treatment 4 (approximately 24 Weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in MSQ at Final Visit Using a 6-Item Questionnaire</measure>
    <time_frame>Baseline, Final Visit (Up to 2 Years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician's Global Impression of Change Using a 7-Point Scale</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization Before and After BOTOX® using a 9-Item Questionnaire</measure>
    <time_frame>Baseline, Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BOTOX® Treatment Regimen for Chronic Migraine</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment Questionnaire: Specific Health Problem Before and After BOTOX® Consisting of 6-Items</measure>
    <time_frame>Baseline, Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Treatment Satisfaction with BOTOX® using a 3-Item Questionnaire</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Beck Depression Inventory Scale at Final Visit Using a 21-Item Questionnaire</measure>
    <time_frame>Baseline, Final Visit (Up to 2 Years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons Why Treatment with BOTOX® Stopped</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Assessment from Patient Diary</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">215</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA (BOTOX®)</arm_group_label>
    <description>Patients diagnosed with chronic migraine headache treated with BOTOX® as standard of care in clinical practice. No intervention was administered in this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>No intervention was administered in this study.</description>
    <arm_group_label>OnabotulinumtoxinA (BOTOX®)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic migraine treated with BOTOX® as standard of care.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patients with chronic migraine eligible to receive treatment with onabotulinumtoxinA
        (BOTOX®) as standard of care.

        Exclusion Criteria:

          -  Diagnosis of hemiplegic migraine, basilar migraine, ophthalmoplegic migraine or
             migrainous infarction, chronic tension-type headache, hypnic headache, hemicrania
             continua or new daily persistent headache.

          -  Patient who is currently taking or planning on taking opioid-containing products,
             barbiturates or combination for acute headache or pain condition.

          -  Treatment with any other botulinum toxin product for any condition within 3 months of
             the screening visit.

          -  Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis
             or any other significant disease that might interfere with neuromuscular function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goran Davidoic</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Caleo Health</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 1B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hys Medical Centre</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 4B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayside Medical Centre</name>
      <address>
        <city>Brentwood Bay</city>
        <state>British Columbia</state>
        <zip>V8M 1P6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeff Oyler</name>
      <address>
        <city>Kamloops</city>
        <state>British Columbia</state>
        <zip>V2C 5T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dhawan Medical Corporation Medical Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>May Ong-Lam</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island Neurology</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V9B 1W3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalhousie University</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Headache Clinic</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Shapero Markham Headache and Pain Treatment Centre</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3R 9X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pain Care Clinics</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5N 6B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Headache &amp; Pain Centre</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M3B 1X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hany Demian</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6K 3Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Medical Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de traitement neurologique</name>
      <address>
        <city>Monthreal</city>
        <state>Quebec</state>
        <zip>H2W 1T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Greene Avenue</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 2A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

